1. Name and Address of Reporting Person
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE MA 02139

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/10/2020

5. Relationship of Reporting Person(s) to Issuer
Director
10% Owner
Chief Medical Officer

10% Owner

Key to Table: A, D, or G indicates an adjustment to shares beneficially owned. (A) indicates an increase in beneficial ownership; (D) indicates a decrease in beneficial ownership; (G) indicates a gain; (D) indicates a loss.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Date of Transaction (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
<th>Number of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/10/2020</td>
<td></td>
<td>M(1)</td>
<td>10,000</td>
<td>$20.93</td>
<td>10,000</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/10/2020</td>
<td></td>
<td>M(1)</td>
<td>10,000</td>
<td>$19.15</td>
<td>20,000</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/10/2020</td>
<td></td>
<td>S(1)</td>
<td>20,000</td>
<td>$74.27</td>
<td>0</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Date of Transaction (Month/Day/Year)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Date Exercisable (Month/Day/Year)</th>
<th>Expiration Date (Month/Day/Year)</th>
<th>Title of Underlying Security (Instr. 8)</th>
<th>Amount or Number of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>08/10/2020</td>
<td>$30.53</td>
<td>10,000</td>
<td>03/08/2020</td>
<td>Common Stock</td>
<td>10,000</td>
</tr>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>08/10/2020</td>
<td>$19.15</td>
<td>10,000</td>
<td>08/10/2020</td>
<td>Common Stock</td>
<td>10,000</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
2. This option is fully vested and exercisable.

/s/ Lori Henderson, as Attorney-in-Fact 08/11/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.